12:00 AM
Mar 22, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Viz: Phase IIb data

An open-label, European and Australian Phase IIb trial in 183 patients showed that high-dose KUR-111 met the primary endpoint of non-inferiority to autologous bone grafting in the proportion of patients who achieved radiological fracture...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >